ArticleProceedings of the National Academy of Sciences of the United States of America2021
AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-Small Cell Lung Cancer.Cancer research · 2026Article
- Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer.PLoS biology · 2026Article
- Exomeres and supermeres: Current advances and perspectives.Bioactive materials · 2025Review
- Inorganic arsenic modulates cell apoptosis by regulating Argonaute 2 expression via the p53 pathway.Toxicology research · 2025Article
- Non-small cell lung cancer organoids: Advances and challenges in current applications.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Effects of multi-walled carbon nanotubes on message and Micro-RNA in human lung BEAS-2B cells.Materials express : an international journal on multidisciplinary materials research · 2024Article
- NCAPG-mediated CDK1 promotes malignant progression of non-small cell lung cancer via ERK signaling activation.American journal of cancer research · 2024Article
- Progress and application of lung-on-a-chip for lung cancer.Frontiers in bioengineering and biotechnology · 2024Review
- Review
- CBX4 deletion promotes tumorigenesis under KrasSignal transduction and targeted therapy · 2023Article
- KRAS Hijacks the miRNA Regulatory Pathway in Cancer.Cancer research · 2023Article
- LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway.Cell cycle (Georgetown, Tex.) · 2022Article
- DNA and RNA Binding Proteins: From Motifs to Roles in Cancer.International journal of molecular sciences · 2022Review
- Pathological implication of protein post-translational modifications in cancer.Molecular aspects of medicine · 2022Review
- Argonaute 2 modulates EGFR-RAS signaling to promote mutantPNAS nexus · 2022Article
- AGO-RBP crosstalk on target mRNAs: Implications in miRNA-guided gene silencing and cancer.Translational oncology · 2022Review
- Interplay between K-RAS and miRNAs.Trends in cancer · 2022Review
- m7G-related gene NUDT4 as a novel biomarker promoting cancer cell proliferation in lung adenocarcinoma.Frontiers in oncology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
Lung cancer is the deadliest malignancy in the United States. Non-small cell lung cancer (NSCLC) accounts for 85% of cases and is frequently driven by activating mutations in the gene encoding the KRAS GTPase (e.g.,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.